Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleBeneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia.
Author(s)Snider SR, Consroe P.
Journal, Volume, IssueNeurology 1985;35(Suppl):201.
Major outcome(s)Improvement of dyskinesia
IndicationParkinson's diseaseAbstract
MedicationCannabidiol

(Fulltext)
In idiopathic dystonia, the terapeutic effect of marijuana smoking is reported to be comparable to diazepam (C.D. Marsden, in Disorders of Movement, 1981,81). The non-psychoactive cannabis derivative, cannabidiol (CBD), also improves dystonia (Consroe and Snider, in Cannbinoids as Therapeutic Agents, in press). We report the effect of CBD on dystonia secondary to Sinemet in parkinsonism, a disorder thought to be a relative contraindication for cannabinoids (D.Moss et al, Pharmacol Biochem Behav 1981, 1984). The patient, a 42-year- old man with an 8-year history of parkinsonism, developed peak-dose dyskinesia about 4 years ago and action dystonia affecting all limbs more recently. Trihexyphenidyl and bromocriptine each produced only slight improvement. To stable optimal dosages of the three drugs, CBD was added, starting with 100 mg/d and increasing by 100 mg weekly. At 100 to 200 mg/d, there was a decrease in clinical fluctuations and in dyskinesia scores (by 30%) without a significant worsening of the parkinsonism. At 300 to 400 mg/d, there was no further improvement in the dyskinesia, and adverse effects (dizziness, drowsiness, increased Parkinson symptoms) appeared. CBD withdrawal resulted in 3 days of severe generalized dystonia and several weeks of increased sensitivity to Sinemet, suggestive of a “drug holiday” effect.

Route(s)Oral
Dose(s)100-400 mg
Duration (days)
Participants1 patient with parkinsonism and secondary dystonia.
DesignUncontrolled case report
Type of publicationMedical journal
Address of author(s)
Full text

[Back to Overview]  [IACM Homepage]


up